Form D · Biotechnology
Blueprint Medicines Corp
Cambridge, MA · CIK 0001597264
Offering snapshot reported Nov 20, 2014 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 10, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 20, 2014 | Initial | $50,000,000 | No comparison | 29 | SEC filing |
| Jan 17, 2014 | Initial | $23,199,996 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-228724
Source: Form D, filed Nov 20, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey W. Albers | Director, Executive |
| Christine Bellon | Executive |
| Alexis Borisy | Director |
| Stephen Knight | Director |
| Kyle Kuvalanka | Executive |
| Christoph S. Lengauer | Executive |
| Nick Lydon | Director |
| Nicholas Lydon | Director |
| Daniel Lynch | Director |
| David Schenkein | Director |
| Thilo Schroeder | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
215 First Street Suite 340/350
Cambridge, MA, 02142
Cambridge, MA, 02142